H. Jack West, MD @JackWestMD Twitter profile

Last Seen Profiles

@atf0mhmd0njm0

@nesli__________

@EnriqueKrauze

@Ganna_cosplay

@YaleMed

@KhurramBar34226

@vgibertini

@HarperPat

@ns_initiative11

@yizhibianfu

@islandermania

@RWuMD

@amitttrmfc

@258c6a8a339c49f

@mahmutkadirkar2

@Jaden2046

@blazeybones

@Jet_C_Thomas

@WasabiCon

@morimoridaisuke

@nadayasaketen1

@METNSTANBU33282

@American_Bridge

@MehmetFaruk_Van

@JasonColeCCDC

@dougcampbell

@bash____ir

@MarissaFlo68884

@ebfc_official

@C5y7FwSgybr64LO

@fswpress

@goguma1989

@r3d_kira

@BrokenMuzzle

@Preens_Lee

@metinvanl290265

H. Jack West, MD

@JackWestMD

2 years

Is there anyone at #ASCO22 , or not, who thinks hotel door bag drop of pharma advertisements is anything but a tone-deaf, disdainful waste of money & paper? To me, it symbolizes an utter lack of ability to adapt to changing times. Don't highlight you're dinosaurs in an Ice Age.

31

16

325

H. Jack West, MD

@JackWestMD

7 months

🚨 Big changes afoot! I'm proud to announce that I've joined Summit Therapeutics ( @Summitplc ) as VP of Clinical Development! I look forward to my colleagues learning more about the company & ivonescimab. No more commentary from me on new data, but I'll contribute as I can.

92

13

293

H. Jack West, MD

@JackWestMD

2 years

KRAS G12C inhibitor sotorasib combined with pembrolizumab for KRAS G12C+ adv NSCLC led to prohibitive hepatotoxicity that required aggressive dose reduction of sotorasib. We've seen similar probs with some other targeted therapies combined w/immunotherapies. #WCLC22

9

68

257

H. Jack West, MD

@JackWestMD

5 years

@Tony_Calles @BrendonStilesMD @WeillCornell @n8pennell @LeciaSequist @StephenVLiu @PatelOncology @GlopesMd @APassaroMD @JordiRemon Not current. My quick algorithm: 1) Check driver mut'ns & PD-L1 2) if EGFR, ALK, ROS1, or BRAF V600E+ -> targeted Rx 3) o/w, if PD-L1 <50% -> chemo/IO (KN189 for nonsquam, KN407 for squam); if PD-L1 > or =50%, pembro mono unless high tumor burden/declining PS (if so, chemo/IO 1L)

11

64

178

H. Jack West, MD

@JackWestMD

5 years

Dr. R. Govindan presents update on ph1 of KRAS G12C mut’n inhib AMG 510 in NSCLC. Impressive results: well tolerated, w/no DLTs up to 960 mg QD; DCR 96%, ORR 48% in evaluable pts. IMO, this is a turning point of effective Rx against tough & common mut’n. #WCLC19 #OncoAlert #LCSM

6

91

173

H. Jack West, MD

@JackWestMD

5 years

Amazing & wonderful to see median surv out at 30+ mo for pts w/high tumor PD-L1 receiving 1st line pembro. That's 28-30% of pts who add to those w/driver mut'ns, & it means we're at point where we're nearing a majority of pts w/adv NSCLC having expectation of living years. #LCSM

Journal of Clinical Oncology

@JCO_ASCO

5 years

Updated analysis of KEYNOTE-024 - pembrolizumab vs platinum-based chemo for advanced NSCLC #lcsm #immunoonc

3

56

83

5

50

165

H. Jack West, MD

@JackWestMD

5 years

Celebrating my lovely wife's birthday tonight. 🎂🎈For the record, I didn't marry someone 25 years younger than me. Amazingly, we're the same age, but no question who wears it better.

16

1

161

H. Jack West, MD

@JackWestMD

4 years

My wife & I are thinking of getting away this weekend, spending it in our guest room for a change of pace.

8

4

161

H. Jack West, MD

@JackWestMD

2 years

I'm so tired of having to reschedule patients for further days out after the lab fails to deliver molecular marker results in the expected time. 😞 The results are the focus of the visit! The most imprecise thing about precision medicine is the turnaround time.

8

15

154

H. Jack West, MD

@JackWestMD

1 year

Ladies & gentlemen, my stepdaughter is amazing! Congrats, Mya!!🔥🔥

Cal Women’s Gymnastics

@CalWGym

1 year

Mya Lauzon locks in her second-straight 9.9+ score on beam with a 9.925! #GoBears 🐻 | #OneDayBetter

3

12

79

15

2

153

H. Jack West, MD

@JackWestMD

6 years

My top 5 #ASCO18 abstracts to check in advanced NSCLC track, both a list & a video w/my explanation giving context for their significance. Check it out. Next will be my top 5 for stage I-III NSCLC, SCLC, & meso. (pls like, comment, & subscribe!) #LCSM

7

69

147

H. Jack West, MD

@JackWestMD

6 years

"Maybe one day, once I have decades of experience as a doctor and further training in my area of specialization, I will be able to speak about health matters with the tone of authority of the average naturopath." How to Counter the Circus of Pseudoscience

3

55

140

H. Jack West, MD

@JackWestMD

4 years

Interesting piece, suggesting we need to take COVID-19 VERY seriously & cancel everything in the foreseeable future.

6

49

128

H. Jack West, MD

@JackWestMD

4 years

For the many who say need to prove OS benefit on ADAURA is obviated by huge magnitude of DFS benefit, here's a stark reminder of outcomes w/EGFR TKI in st 4 in OPTIMAL, courtesy of @BenjaminBesseMD . Think of this in discussions of DFS vs. OS to define SOC in adjuvant setting.

12

32

130

H. Jack West, MD

@JackWestMD

6 years

From this week's @JAMAOnc : "Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors". This is largest evaluation of this topic, providing details of how , when, from what regimens, & how often fatalities from immunotherapy occur. Worth knowing.

7

108

124

H. Jack West, MD

@JackWestMD

6 years

My top 5 practice-changing highlights in LC for 2017 1) PACIFIC trial: durvalumab in st 3 NSCLC 2) FDA approval of KN-21g 3) FDA approval of NGS for adv solid tumors 4) FLAURA: osimertinib in 1L EGFR mut+ 5) Mounting IO data in SCLC (ALEX is #6 bec ALK only 4%) Thoughts? #LCSM -

5

64

122

H. Jack West, MD

@JackWestMD

7 years

Your quick guide to #ASCO17 #LungCancer presentations in 2 images. Here's my top 10 to watch for, & their potential implications #LCSM

4

97

123

H. Jack West, MD

@JackWestMD

1 year

🚨 Though there are >5 notable abstracts in lung cancer at #ASCO23 , here's a vid of my TOP 5 in lung cancer to focus on & why I consider them so directly relevant. (note in my ASCO podcast w/ @VamsiVelcheti , we don't cover LBAs; 4 of these 5 are LBAs).

0

43

124

H. Jack West, MD

@JackWestMD

4 years

Just brought home cockapoo puppy, Kira. Was she named after Olivia Newton-John's character in 1980 movie, Xanadu? 👍 But my wife has an even deeper crush on this one than I did on ONJ's Kira. I've been displaced as recipient of her unconditional love. What have I done?

15

1

122

H. Jack West, MD

@JackWestMD

11 months

#ASCO23 A9002 (Wang): EGFR exon 20 TKI sunvozertinib appears to be quantum leap over current options for this target, w/ORR 60.8%, active vs. broad range of ex 20 mut'ns, good activity in brain (icRR 48.5%); tox notable for diarrhea & rash, mostly gr 1-2. Real step forward. #LCSM

6

36

122

H. Jack West, MD

@JackWestMD

6 years

Its official! Hell has frozen over! Dr. Liu presents IMpower133 trial that shows significant improvement in OS along w/PFS, relatively broad benefits (though not seen in pts w/brain mets), & no unexpected or prohibitive safety signals. Should be practice-changing. #WCLC2018 #LCSM

6

43

114

H. Jack West, MD

@JackWestMD

4 months

My narrative review with @DrJaeYKim on the changing landscape in early stage NSCLC, newly published in @JAMAOnc , covering the data w/some commentary on management options: We welcome people's thoughts!

4

34

110

H. Jack West, MD

@JackWestMD

1 year

ADAURA data are consistently hyped as showing long-term DFS benefit rather than characterizing results accurately, which should be "DFS benefit erodes immediately & profoundly after prolonged treatment ends, but it's enough to prop up DFS overall, for now (& don't ask about OS)"

4

25

109

H. Jack West, MD

@JackWestMD

5 years

Several wks ago, I asked about whether anyone has stat/image capturing theprogress made in lung cancer over past few decades. That has been hard to find. This image is my attempt, & a bit crude, but plotting med OS w/so many developments in that time. Work in progress. #LCSM

6

34

106

H. Jack West, MD

@JackWestMD

4 years

As my employer @cityofhope & many other orgs implement travel restrictions, are we talking yet about potential implicat'ns of #COVID -19 on #AACR20 & #ASCO20 ? I'm sure prof societies don't want to harm conference attendance, but this would be great yr for live streaming option.

12

11

104

H. Jack West, MD

@JackWestMD

11 months

This👇 ADAURA is unfortunately a trial of 100% access to osi vs <50% access to osi among pts w/EGFRm+ NSCLC, not adjuvant osi for all vs osi for pts at relapse, as needed. Clearly, if pts got anything other than osi at relapse, it means they weren't too ill, but got worse Rx.

5

24

97

H. Jack West, MD

@JackWestMD

4 years

Great week!! Approvals for RET fusion-positive & MET exon 14 mutation-positive NSCLC this week. If there were holdouts not yet doing NGS for adv NSCLC, there shouldn’t be now. There are so many targets w/highly effective agents, & we can’t afford to miss them. #LCSM

Alexander Drilon MD

@alexdrilon

4 years

FDA approves selpercatinib for RET-dependent lung and thyroid cancers!! Line agnostic. 🤩🤩🤩So many patients and researchers to thank for this groundbreaking moment. Can’t fit them all here!!

16

81

284

2

32

94

H. Jack West, MD

@JackWestMD

5 years

Note: comparator in 2019 is no longer chemo alone but chemo/pembro (for any IO-eligible pt) or pembro mono (most appropriate for high PD-L1). Not sure these data should compel us to abandon current standards. Also, chemo-free shouldn't be misinterpreted as toxicity-free. #LCSM

Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ

@APassaroMD

5 years

💥 #ESMO19 #LCSM Results of CM-227 On t way of a chemo-free new era in #lungcancer for neg PDL1 pts in 1L (17.1 vs 12.2) (HR 0.62) 2yr OS rates of 40% vs 32.8% in favour of nivo+ipi. Data presented by @peters_solange and just published on @nejm

1

31

53

6

30

91

H. Jack West, MD

@JackWestMD

8 months

TBH, this wasn't on my bingo card, but these results are remarkable. They convincingly eclipse what we've seen w/chemo/atezo & chemo/durva. Wow. 🤯 Literally change what I though was possible in ES-SCLC. #OncoAlert #LCSM

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

@RManochakian

8 months

🔥🚨Hot off the press, presented @IASLC #WCLC23 , results of ETER701, phase 3 trial of Benmelstobar+Anlotinib+Chemo vs Placebo+Chemo in 1st line therapy for extensive stage ES #SCLC Unprecedented historical IMPROVEMENT in #PFS & #OS mPFS 6.9 vs 4.2 months mOS 19.3 vs 11.9 months

5

69

123

9

31

94

H. Jack West, MD

@JackWestMD

2 years

One troubling result of approval of neoadjuv chemo/nivo for resectable NSCLC based on CheckMate 816: I’m now seeing cases that have historically been unresectable (3B, even 3C) now shoehorned into neoadjuvant chemo/IO because pt & surgeon are gravitationally pulled to surgery.

6

16

93

H. Jack West, MD

@JackWestMD

5 years

Dr. @alexdrilon reports on LOXO-292, newly christened selpercatinib in pts w/RET fusion-pos NSCLC. Terrific ORR of 91%, Med PFS 18.4 mo. Minimal drug-related toxicity grade 3 or higher. For the 2% of pts w/RET, a tremendous advance. Need approval ASAP. #WCLC19 #LCSM #OncoAlert

2

45

90

H. Jack West, MD

@JackWestMD

5 years

Huge congrats to @HwakeleeMD on her election as President of @IASLC . Well-deserved: your dedication, leadership, & ideas will be great for the organization and the entire field of lung cancer. #LCSM

0

17

89

H. Jack West, MD

@JackWestMD

2 years

Dr. @BenjaminBesseMD makes great point subgroup of pts w/PD-L1 >50% is not homogeneous, but pts w/PD-L1 90% or higher are major drivers of benefit w/immune checkpoint inhibitors. How much of benefit seen in high PD-L1 (50% cutoff) is driven by pts w/very high PD-L1? #WCLC22

1

15

89

H. Jack West, MD

@JackWestMD

5 years

Heading off to #ASCO19 , I get a motion detection alert from my outdoor camera. It's a cute brown bear, just passing through. This is why we don't leave food trash outside. They sometimes take a dip in the pools in our neighborhood.

6

3

89

H. Jack West, MD

@JackWestMD

10 months

Let's be clear: OS results are neg for OS benefit in PD-L1+ NSCLC. If we're going to rely on smaller subgroups to highlight the HR of 0.43 for those w/high PD-L1, we should also note HR for OS was 0.95 (i.e., NO trend of OS benefit) for those w/PD-L1 1-49%. As w/KN-042. With…

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

@RManochakian

10 months

🔥🚨JUST OUT @Annals_Oncology Overall survival data of #IMpower010 , #Adjuvant #Atezolizumab in resected stage II-IIIA #NSCLC At 45 months F/U, OS immature but positive trend favoring atezo in PD-L1 subgroups. HR: 0.71 for PDL1+ 0.43 for PDL1 ≥ 50% 👇🏼

0

16

51

5

19

88

H. Jack West, MD

@JackWestMD

2 years

My stepdaughter, Mya Lauzon, is on the left, having debuted in her 1st NCAA gymnastics tournament this past weekend, w/strong showing in 3 events. It's only the beginning for her. Couldn't be more proud! She's going to do great things both in & outside the gym. #GoBears

Cal Women’s Gymnastics

@CalWGym

2 years

Quite the debut from this pair of freshmen!

0

8

83

11

0

86

H. Jack West, MD

@JackWestMD

6 years

A frustrating issue of #PrecisionMedicine : I just rec'd Foundation One report on a pt that took 28 pages & 310 refs to report a few completely non-actionable mut'ns of no clin value. Never has it taken so long to say so little. Verbosity ≠ value.

5

19

86

H. Jack West, MD

@JackWestMD

6 years

Wow. Another IO trial positive! 1st line pembrolizumab (Keytruda) monotherapy in both squamous & non-squamous NSCLC beats doublet chemo in OS for not only pts w/high PD-L1 express'n threshold of 50%, but even in those w/PD-L1 1% or higher. #LCSM

8

53

85

H. Jack West, MD

@JackWestMD

2 years

Today's #WCLC22 Plenary Session is dedicated to #oligometastatic disease, long an aspect of lung cancer management for a minority of pts, but I feel as if this is a coming out party for the concept on the big stage as it turns a corner in greater dedicated study & practice. #LCSM

1

19

84

H. Jack West, MD

@JackWestMD

6 years

I agree w/discussant @DrRoyHerbstYale that results of KEYNOTE-189 exceeded expectations. Even knowing trial was positive, I'm impressed. These diffs are compelling. #AACR18 #LCSM

3

39

81

H. Jack West, MD

@JackWestMD

6 years

Novel ph 2 trial presented by @Jbauml of RT to primary oligometastatic NSCLC followed by pembrolizumab, showing nice results that exceed historical data. Suggest particular benefit of immunotherapy after radiation to sites of gross disease in oligometastic NSCLC. #WCLC2018 #LCSM

3

42

81

H. Jack West, MD

@JackWestMD

8 months

As w/ADAURA, I'd say DFS is a much lower & less meaningful bar than OS (& I am disappointed onc community has become so complacent & pharma-aligned about this), but I'd give pts benefit of doubt & favor treating w/adjuv alectinib based on this. We should pay attention not only to…

Genentech

@genentech

8 months

#Breaking : Today we announced that our Phase III trial in ALK-positive early-stage NSCLC met its primary endpoint. Learn more:

3

21

71

2

18

82

H. Jack West, MD

@JackWestMD

5 years

Remarkable diffs in clinical outcomes w/checkpoint inhibs assoc'd w/developing immune-related adverse events, as reported here: Preexisting Antibodies in Patients Treated With Anti–PD-1 for Advanced Non–Small Cell Lung Cancer @JAMAOnc #LCSM

7

44

82

H. Jack West, MD

@JackWestMD

11 months

Very nice discussion by @DrMarkAwad putting KN-671 into context & asking important Qs about clinical implications in an increasingly crowded setting. #ASCO23 #LCSM #OncoAlert

0

24

80

H. Jack West, MD

@JackWestMD

1 year

I'd heard that @ASCO has dog therapy & am hoping that's not just a rumor. Can someone confirm if there will be access to dogs, ideally a few puppies, for a little de-stressing time at #ASCO23 ? I need to put it on my schedule...

8

4

80

H. Jack West, MD

@JackWestMD

2 years

Dr. @BenjaminBesseMD concludes IMpower010 OS results good enough to use atezo, but we can't focus on subgrp analysis. 🤔OS results for PD-L1+ are neg thus far, only pos if you focus on PD-L1 high pts. You can't rely on subgroups to call trial pos, then say ignore subgrps. #WCLC22

4

12

78

H. Jack West, MD

@JackWestMD

2 years

This has always been a pivotal study, but now, seeing PFS >14% higher 5 years out, 4 years after consolidation therapy has ended, IMO we should conclude this has truly moved the needle (A LOT) on cure rates in this setting. More than concurrent vs. sequential chemo/RT. #LCSM

Yüksel Ürün

@DrYukselUrun

2 years

PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer : 🔶5-year OS: 43%🆚33% PFS: 33%🆚19% 🔶"Durvalumab after CRT as the SOC for patients with unresectable, stage III NSCLC" @JCO_ASCO @OncoAlert @ASCO @IASLC

2

52

150

3

22

79

H. Jack West, MD

@JackWestMD

6 years

Editorial in @JCO_ASCO on tumor mutation burden (TMB) appropriately expressing caution over using it in clinic, particularly in managing adv NSCLC, based on limited data available thus far. Worth a read. #LCSM

3

38

77

H. Jack West, MD

@JackWestMD

6 years

. @myESMO President Elect @peters_solange speaking at #WCLC2018 Plenary, reminding us that developments in #cancer care are only valuable to extent they're available to pts, which varies remarkably around world. Need to get pts everywhere access to best therapy. #CancerGroundshot

1

32

77

H. Jack West, MD

@JackWestMD

6 years

Conclusions by Dr. Helena Yu from MSKCC. Nice job on a complex & increasingly broad topic on EGFR inhibitor options, sequencing, acquired resistance management, & potential combinations. #ASCO18 #LCSM

2

41

76

H. Jack West, MD

@JackWestMD

3 years

So proud my step-daughter Mya Lauzon will be heading to Cal-Berkeley, competing with their nationally renowned gymnastics team starting next year! She's amazing. 🤩 Go Bears! 🐻

Cal Women’s Gymnastics

@CalWGym

3 years

Excited to announce the four newest members of the Golden Bears squad.

2

6

30

5

0

77

H. Jack West, MD

@JackWestMD

5 years

My current @MedscapeOnc column takes a sobering look at how real world evidence highlights our dismal failure in executing on the promise of precision medicine in practice for advanced lung cancer. Please give it a read. I'd love your thoughts. #LCSM

'How Could We Fail so Miserably?'

A new study using real-world data suggests that far too many patients with driver mutations are dying without receiving effective treatments.

www.medscape.com

21

23

76

H. Jack West, MD

@JackWestMD

1 year

The answer here is NO. Having another option that provides no evidence of superiority but adds a year of treatment, w/its attendant toxicities & financial costs, is damning w/faint praise. We don't need another option that offers no incremental benefit over what we already have.

Jarushka Naidoo

@DrJNaidoo

1 year

#AACR23 Is #AEGEAN a practice-changing study by @DrRoyHerbstYale ? - with similar outcomes to CM816, AEGEAN represents a new option of periop chemo-IO + 1 yr IO - does not replace CM816 - does not address what adj IO adds, therefore a lateral move on practice @OncoAlert #LCSM

1

35

99

4

15

76

H. Jack West, MD

@JackWestMD

8 months

When a great contributor to the field is also a great person. 🤩

Sandip Patel MD

@PatelOncology

8 months

⁦ @RamalingamMD ⁩ well deserved winner of the Paul Bunn Jr Scientific Award ⁦ @IASLC ⁩ #wclc23

8

16

122

0

3

76

H. Jack West, MD

@JackWestMD

10 months

⭐️ Important trial that didn't get much attention when presented last yr, but it will lead me to consider single-agent atezo more favorably in this pop'n. Notable that benefit of atezo over single agent chemo was seen even in pts w/tumor PD-L1 express'n low or 0. #LCSM #OncoAlert

Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation

@RManochakian

10 months

🔥🚨Hot off the press @TheLancet #IPSOS phase 3 trial of 1st line #Atezolizumab monotherapy vs single-agent #chemotherapy in pts with advanced #NSCLC ineligible for a platinum-containing chemo. Study showed better #OS & #Quality of life with Atezo. 👇🏼

5

40

103

7

24

75

H. Jack West, MD

@JackWestMD

1 year

Nice to see an insurance company held accountable for denying care. Just wish it hadn't been for an intervention that is actually w/o evidence of superiority in nearly all settings in which it is used, 3x more expensive than conventional RT, & is market > data-driven.

Shaalan Beg MD MBA FASCO

@ShaalanBeg

1 year

I guess it is possible for insurance companies to be held liable for denying care. In these cases, they classified proton therapy as experimental for certain Indications. 🤔

3

6

27

11

17

74

H. Jack West, MD

@JackWestMD

5 years

Sorry. Lest a hapless reader be misled by this, TMB is NOT a test that has ever been shown to improve outcomes in lung cancer management by using it, is not a standard of care now, & is still far more sizzle than steak. Maybe different w/more data, but today hype >> good data.

OncLive.com

@OncLive

5 years

Evidence Grows for Tumor Mutational Burden as Predictor of Immunotherapy Success

0

2

8

4

20

72

H. Jack West, MD

@JackWestMD

11 months

I've said "ship has sailed" & results justify adjuv osi. However, IMO, you/we should give less 👏📣& openly acknowledge major, systematic ethical/scientific probs that compromise if not undermine ADAURA interpretation. We shouldn't just REWARD cheating that HARMS pts on ctrl arm.

Nathan A. Pennell MD, PhD, FASCO

@n8pennell

11 months

@JackWestMD This is exactly why I think it’s time to stop debating ADAURA as I think this will be widely adopted, and move on to answering important questions about the appropriate duration of therapy, and which patients truly need any treatment, indefinite treatment versus de-escalation

7

2

21

7

13

71

H. Jack West, MD

@JackWestMD

6 years

For anyone looking to follow many lung cancer docs on twitter, from various disciplines, I've created a list to follow: … I apologize in advance for oversights & am happy to add people as suggested. #LCSM

15

36

73

H. Jack West, MD

@JackWestMD

6 years

For all the talk about targeted therapy or immunotherapy making chemo obsolete, the biggest wins in lung cancer at #ASCO18 came from combining chemo w/1st line immunotherapy or EGFR TKI. Seems to be killing distinct cancer cell populations.

1

37

70

H. Jack West, MD

@JackWestMD

6 years

Heading on a late flight to #AACR18 tonight to see & relay hugely important trial results from KEYNOTE-189 & CheckMate-227 trials, among other for advanced NSCLC. Stay tuned: big session starts 10:30 AM Central. #LCSM

3

19

70

H. Jack West, MD

@JackWestMD

2 years

Nobody says it better. Thank you for being the voice of reason. If we don't laugh, we cry!🥂😩

Dr. Glaucomflecken

@DGlaucomflecken

2 years

Nature does open access

984

29K

91K

1

18

70

H. Jack West, MD

@JackWestMD

4 years

Practice changing. Kudos for providing a definitive answer to a question we've struggled with for decades. #LCSM

soria

@jsoriamd

4 years

#ESMO20 LungART trial sponsored by @GustaveRoussy in collaboration with @IFCT SAKK UK NCRI @Institut_cancer is an academic effort with 501 patients, no statistical advantage of PORT in pN2 resected NSCLC with HR of 0.85 (0.61-1.07) with an excess of death (with more CV)

1

54

116

1

14

70

H. Jack West, MD

@JackWestMD

1 year

Happy to share editorial by @christine_lovly & me in @JCOOP_ASCO discussing critical need to provide support for oncologists in interpreting biomarker testing; we feel it's a critical shortcoming even if we have tissue & solve TAT. Welcome your thoughts:

Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support...

ascopubs.org

4

19

70

H. Jack West, MD

@JackWestMD

5 years

A central Q in long term F/U of biomarker unselected recipients of pembrolizumab for adv NSCLC, w/OS 25-30%, is whether these pts are cured. Dr. Garon expresses certainty: "I don't know"...but who would have imagined a few years ago that this would be a legit Q? #ASCO19 #LCSM

6

24

69

H. Jack West, MD

@JackWestMD

3 years

@marklewismd Great observation. All reason to wince thinking about the anti-vaxx campaign around this. A great opportunity to reflect on the value of placebo arms and denominators in clinical research.

0

69

H. Jack West, MD

@JackWestMD

8 years

w/o data, #PrecisionMedicine is more sizzle than steak. My @JAMAOnc viewpoint: we need far more evidence, less hype.

6

39

67

H. Jack West, MD

@JackWestMD

4 years

It's now official. #ASCO20 broke the internet! 😫😠

Tatiana Prowell, MD

@tmprowell

4 years

Oncologists are optimists by nature. Therefore I choose to interpret #ASCO20 mtg site disruption as a sign that you're all storming the site. A good thing about virtual format: the content is all there now & not going anywhere, so make some tea & say hi to your family.😃

2

4

78

2

7

69

H. Jack West, MD

@JackWestMD

3 years

Man, that was beautiful and inspiring. Should go down in history as a highlight of today.

Vincent Rajkumar

@VincentRK

3 years

This thread will be incomplete without the video. The delivery was special.

2

16

77

3

4

69

H. Jack West, MD

@JackWestMD

1 year

I love that @christine_lovly can make complex science accessible: a tremendous communicator, terrific talk at #TexasLung23 . Great start to today's sessions.

4

9

68

H. Jack West, MD

@JackWestMD

5 years

Amazing to be talking about 5 yr survival in previously treated patients w/metastatic NSCLC, & especially to note it in 30% range for those w/PD-L1. Redefines what is possible in lung cancer. #LCSM

the limbic

@thelimbiconc

5 years

Lung cancer results from #ASCO19 : KEYNOTE 1 - pembrolizumab 5yr survival rates in advanced #nsclc were 23.2% for previous untreated patients and 15.5% for previous treated patients - and in patients with PD-L1 expression of 50% or more OS was 29.6% vs 15.7% for those with 1-49%

1

22

49

0

20

69

H. Jack West, MD

@JackWestMD

4 years

Our medical system is badly broken. @JAMAOnc paper out today shows even radiation oncologists couldn't find anticipated charges for standard #ProstateCancer radiation at many #cancer centers, & when they could, they found a >20-fold variability in cost.

Price Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated...

This economic evaluation of prostate cancer radiation therapy costs at National Cancer Institute–designated cancer centers assesses the value of the price transparency mandate of the US Centers for...

jamanetwork.com

5

31

67

H. Jack West, MD

@JackWestMD

5 years

Dr. Google Is a Liar @nytimes editorial highlights harm from "medical fake news" online. Best response is to counter w/plenty of credible online info for pts. It's what @DrJenGunter & @CancerGRACE are doing & should be a broad commitment by med community.

5

20

68

H. Jack West, MD

@JackWestMD

5 years

Hugely important development:

2

30

68

H. Jack West, MD

@JackWestMD

5 years

Dr. @rdoebele offering commentary on selpercatinib trial argues that trials of targeted therapy like this (& I would argue also AMG 510 for KRAS G12C mut’n+ NSCLC, at least in later line) don’t need phase 3 rand trials vs. chemo-based treatment. Agree. #WCLC19 #LCSM #OncoAlert

4

26

69

H. Jack West, MD

@JackWestMD

8 months

I have an oncology joke, but I need to test first to see if you're likely to respond.

Shematologist, MD

@acweyand

8 months

I have a pediatrics joke, but it’s not fully developed.

77

72

880

3

6

68

H. Jack West, MD

@JackWestMD

6 years

This will be an amazing @AACR session on #immunotherapy combo studies in adv NSCLC Mon 4/16 10:30A: KN-189, CM-227, TMB cutoff from CM-568, & IMpower150 by PD-L1 express'n. Worth going to Chicago just for this pivotal session. #LCSM

2

27

66

H. Jack West, MD

@JackWestMD

6 years

Among key benefits w/osimertinib in EGFR mut+ NSCLC is efficacy vs CNS mets & reduction in rate of CNS progress'n. This @JCO_ASCO paper is on CNS efficacy of osi vs cis/pem in T790M+ acq'd resistance (AURA3 trial), but it's also critical in 1st line. #LCSM

2

31

65

H. Jack West, MD

@JackWestMD

6 years

Based on highly pos results of KN-189 trial, combo of pembro w/platinum-pemetrexed chemo rec's full @US_FDA approval in adv non-squam NSCLC that is EGFR/ALK neg, regardless of level of tumor PD-L1 expression. Expected & appropriate. #LCSM

0

34

65

H. Jack West, MD

@JackWestMD

7 years

Looking forward to #ESMO17 in Madrid (both conf presentations & Madrid!). My top 5 in lung cancer. Follow me for data & commentary. #LCSM

2

44

64

H. Jack West, MD

@JackWestMD

4 years

9th key development in #LungCancer over past decade is change of std of care in ext stage SCLC after >15 yrs, w/significant improvement from addition of atezolizumab or durvalumab to platinum/etoposide chemo. Vy comparable benefits seen in 2 trials. #LCSM #OncoAlert

Charu Aggarwal, MD, MPH, FASCO

@CharuAggarwalMD

4 years

10. #Screening for #LungCancer WORKS! NELSON trial presented @IASLC #WCLC2018 : CT scans ⬇️ mortality, by 26% in high-risk men, 39% in high-risk women over a 10-year period. Confirms NLST . Call to action: Implement Lung Cancer Screening Programs @OncoAlert

5

18

50

1

33

62

H. Jack West, MD

@JackWestMD

4 years

Mic drop. @n8pennell wins twitter today.

Nathan A. Pennell MD, PhD, FASCO

@n8pennell

4 years

Thoracic oncologists in the days leading up to the ADAURA data being released: #ASCO20 #LCSM

21

87

404

3

11

63

H. Jack West, MD

@JackWestMD

5 years

My wife & I are visiting my folks in #Cleveland , took Dad to a #Browns game.

6

0

63

H. Jack West, MD

@JackWestMD

6 years

Time to highlight that we are now in an era when pts w/rare cancers are increasingly likely to know more than docs, even very good ones, about their dzs. This @ros1cancer page on Drugs to Treat ROS1+ NSCLC deserves its place at top of Google search: #LCSM

5

32

65

H. Jack West, MD

@JackWestMD

8 months

Particularly when many of these patients are quite young, our celebrating their relatively longer survival in years that you can still count on the fingers of one hand likely seems tone deaf.

Ramy Sedhom, MD

@ramsedhom

8 months

We forget median OS for EGFR mutated lung cancer is ~3 years, >40% with grade III adverse events I worry about the culture in oncology where these patients are seen every 3 months & we ignore their existential/emotional/symptom needs cc: @JackWestMD

11

21

96

9

6

65

H. Jack West, MD

@JackWestMD

4 years

Someone please tell me I'm not the only one who finds it infuriatingly disingenuous to have every recorded hold message say that the company is experiencing "unusually long hold times" when it has been like this invariably for months? 😠 Hire help & give actual customer service.

3

63

H. Jack West, MD

@JackWestMD

5 years

CheckMate-9LA: nivo/ipi added to chemo (2 cycles) -> signif better OS than chemo alone for 1L adv NSCLC: - no details yet. IMO, nivo/ipi appeal is as chemo-free option (e.g., CM227); I don't see CM9LA as better choice than KN189 or KN407. #LCSM #OncoAlert

4

23

64

H. Jack West, MD

@JackWestMD

6 years

Dr. Leena Gandhi makes critical point that KN-042 trial did not permit crossover from chemo to pembro upon PD, but only 20% of pts on chemo Rex’s any immunotherapy post-progression. Big shortcoming. Overwhelming majority of pts should get 2nd line IO as std of care. #ASCO18 #LCSM

2

29

64

H. Jack West, MD

@JackWestMD

4 years

As we should have expected, @ASCO announces #ASCO20 Annual Conf Live Meeting is cancelled but will be replaced by virtual presentations. We'll need to see how it's executed, but it's clearly the right, arguably only choice. #OncoAlert

1

10

62

H. Jack West, MD

@JackWestMD

4 years

In a startling turn of events, I'm going to say that beyond needing to see actual data here, we need to see pCR correlation w/OS in lung cancer before declaring it a new std of care. Lower bar & faster answer, yes, but it is not an established surrogate in lung cancer thus far.

Stephen V Liu, MD

@StephenVLiu

4 years

#OncoAlert Phase 3 CheckMate 816 study meets its primary endpoint. Addition of neoadjuvant nivolumab to chemo in resectable NSCLC improved pathological CR rate ca chemo alone. Awaiting full data set. Is pCR a valid surrogate for OS in this setting? #LCSM

9

38

87

4

8

61

H. Jack West, MD

@JackWestMD

10 months

Sadly, med community is comprised too much of 🐑, rule followers too timid to reject the status quo, even if they see things as pointless or harmful. If you think MOC is good, say it. Otherwise, if you don't sign, ask yourself why you don't have the courage & character to do…

Aaron Goodman - “Papa Heme”

@AaronGoodman33

10 months

Is there one physician in the universe (other than a doc who works for ABIM) that supports MOC and thinks it’s a good thing? Petition · Eliminate ABIMs MOC requirement ·

9

15

85

11

10

63

H. Jack West, MD

@JackWestMD

1 year

🔔Just released commentary piece by @ADesaiMD , Caleb Smith, & myself about distinctions between FDA approval of cemiplimab w/chemo & non-approval of sintilimab, along w/suggestion of benefits of FDA breaking its categorical refusal to consider cost 💵:

6

17

62

H. Jack West, MD

@JackWestMD

4 years

A gain for @Novartis is a stinging loss for academic medicine. Alice Shaw will be missed at Mass General & throughout #LungCancer community. She has also been among the most connected with online patient communities like @ALKLungCancer & @ros1cancer . #LCSM

Endpoints News

@endpts

4 years

Shaw has been a beloved physician and an astonishingly prolific Harvard academic, pioneering targeted treatments for ROS, RET and ALK mutant cancers. Now she will step inside the walls of a longtime industrial collaborator, Novartis. Alice Shaw @Novartis

0

5

15

1

15

62

H. Jack West, MD

@JackWestMD

1 year

Mya gets a 9.95 on beam in first @CalWGym home meet of this season. Mya, you ROCK!

11

4

64

H. Jack West, MD

@JackWestMD

2 years

My potentially controversial conclusion from OS data on IMpower010: ⭐️Knowing what we do about DFS & OS benefit in pts w/1-49% PD-L1 (HR 0.87 & 0.95, respectively), it is a POOR choice to recommend a year of adjuvant atezo for this group, despite FDA approval. Thoughts?

Dr. Estela Rodriguez

@Latinamd

2 years

Monday. Coming back from @iaslc #WCLC22 I already showed this #IMPower010 graph showing #atezolizumab OS benefit in resected high PDL1+ cohort to 2 pts in clinic (w high PDL1) 👉OS endpoint definitely more reassuring than DFS in adjuvant setting. #lcsm

0

9

23

11

14

64

H. Jack West, MD

@JackWestMD

6 years

. @US_FDA finally approves osimertinib for 1L in EGFR mut+ NSCLC - tho some favor saving it for 2L, IMO that's poor choice, since only 50-60% have T790M+ acq'd resistance & qualify for it. 100% can get it 1L. PFS far better, CNS activity, lower tox. #LCSM

4

29

62

H. Jack West, MD

@JackWestMD

8 months

Completely believable. We've really needed a trial to help distinguish good outcomes from surgery vs. good outcomes from being a cherry-picked candidate for surgery. Now we need to see if people accept data or if we won't let randomized data get in the way of our biases.

Patrick Forde

@FordePatrick

8 months

#mars2 now online - surgery for mesothelioma 👀 big rethink on the way? #mesothelioma #WCLC2023

9

59

110

7

14

63

H. Jack West, MD

@JackWestMD

4 years

I didn't put out a #WestWind episode today. I'm putting it on hiatus after >100 episodes over >13 months. I need to reflect on how to move it forward, who to speak to. May do more video-based work for a while, alone +/- with colleagues over Zoom, etc. Thanks to all supporters.

4

2

61

H. Jack West, MD

@JackWestMD

2 years

Honored to accept award for Clinical Innovation on behalf of @myaccesshope @cityofhope for model of care delivery providing subspecialist insight & support for pts w/cancer throughout the US.

HemOnc Today

@HemOncToday

2 years

Clinical innovation award goes to AccessHope program from @cityofhope with @JackWestMD accepting #HealioInnovators

1

2

16

3

13

61

H. Jack West, MD

@JackWestMD

3 years

Dr. Socinski: pooled analysis of OS of irAEs in 3 atezo trials in adv NSCLC. Remarkable to see signif better OS (&ORR) in pts w/irAEs not only among recipients of atezo but ALSO in ctrl arm. Echoes EGFR AE data for rash. Something about pt constitution? biol dose? #ASCO21 #LCSM

16

23

61